Neutrophil gelatinase-associated lipocalin as diagnostic and prognostic tool for cardiovascular disease and heart failure

Expert Opinion on Medical Diagnostics

Volumn 7, Issue 2, 2013, Pages 209-220

  Iqbal, Navaid ^a   Choudhary, Rajiv ^a   Chan, Jeffrey ^a,b   Wentworth, Bailey ^a   Higginbotham, Erin ^a   Maisel, Alan S ^a,b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute kidney injury; Biomarkers; Liver fatty acid binding protein; Neutrophil gelatinase associated lipocalin; Percutaneous coronary intervention

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; APOLIPOPROTEIN B; BRAIN NATRIURETIC PEPTIDE; CREATINE KINASE MB; CREATININE; CYSTATIN C; FATTY ACID BINDING PROTEIN; FIBRINOGEN; GALECTIN 3; GELATINASE B; INTERLEUKIN 18; LIPOPROTEIN A; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROADRENOMEDULLIN; ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; LCN2 PROTEIN, HUMAN; LIPOCALIN; ONCOPROTEIN;

ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR MORTALITY; CONTRAST INDUCED NEPHROPATHY; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIAGNOSTIC VALUE; DISEASE SEVERITY; DRUG HALF LIFE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE; HEART VENTRICLE REMODELING; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; HYPERTENSION; INNATE IMMUNITY; KIDNEY CONCENTRATING CAPACITY; KIDNEY FUNCTION; KIDNEY INJURY; LEUKOCYTE ACTIVATION; PREDICTIVE VALUE; PROGNOSIS; PROTEIN DEGRADATION; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; THROMBOCYTE ACTIVATION; UNSTABLE ANGINA PECTORIS; UPREGULATION; CARDIOVASCULAR DISEASE; METABOLISM;

ACUTE-PHASE PROTEINS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HEART FAILURE; HUMANS; LIPOCALINS; PROTO-ONCOGENE PROTEINS;

EID: 84874331550     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2013.763795     Document Type: Article

References (93)

1. Cardiovascular Diseases Factsheet #317. In: World Health Organization. Available from: http://www.who.int/mediacentre/factsheets/fs317/en/index.html [Accessed 24 September 2012]
2. European Cardiovascular Disease Statistics 2008. In: European Heart Network. Available from: http://www. ehnheart.org/cvd-statistics.html [Accessed 24 September 2012]
3. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2012 update. A report from the American Heart Association. Circulation 2012;125:e2-e220
4. Cowland JB, Borregaard N. Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics 1997;45:17-23
5. Yang J, Goetz D, Li JY. An iron delivery pathway mediated by a lipocalin. Mol Cell 2002;10(5):1045-56
6. Mori K, Leet HT, Rapoport D, et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 2005;115:610-21
7. Elneihoum AM, Falke P, Hedblad B, et al. Leukocyte activation in atherosclerosis: correlation with risk factors. Atherosclerosis 1997;131:79-84
8. Zografos T, Haliassos A, Korovesis S, et al. Association of neutrophil gelatinase-associated lipocalin with the severity of coronary artery disease. Am J Cardiol 2009;104:917-20
9. Hemdahl AL, Gabrielsen A, Zhu C, et al. Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler Thromb Vasc Biol 2006;26:136-42
10. Lindberg S, Pedersen SH, Mogelvang R, et al. Prognostic utility of neutrophil gelatinase-associated lipocalin in predicting mortality and cardiovascular events in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol 2012;60:339-45
11. Sahinarslan A, Kocaman SA, Bas D, et al. Plasma neutrophil gelatinase-associated lipocalin levels in acute myocardial infarction and stable coronary artery disease. Coron Artery Dis 2011;22:333-8
12. Mishra J, Mori K, Ma Q. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 2004;15:3073-82
13. Mishra J, Ma Q, Prada A, et al. Identification of NGAL as a novel early urinary marker for ischemic renal injury. J Am Soc Nephrol 2003;14:2534-43
14. Kjeldsen L, Johnsen AH, Sengeløv H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993;268:10425-32
15. Miethke M, Skerra A. Neutrophil gelatinase-associated lipocalin expresses antimicrobial activity by interfering with L-norepinephrine-mediated bacterial acquisition. Antimicrob Agents Chemother 2010;54:1580-9
16. Flower DR. The lipocalin protein family: structure and function. Biochem J 1996;318:1-14
17. Zappitelli M, Washburn KK, Arikan AA, et al. Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children: a prospective cohort study. Crit Care 2007;11:R84
18. Mishra J, Dent C, Tarabishi R. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 1998;356:1231-8
19. Makris K, Markou N, Evodia E. Urinary neutrophil gelatinase-associated lipocalin (NGAL) as an early marker of acute kidney injury in critically ill multiple trauma patients. Clin Chem Lab Med 2009;47:79-82
20. de Geus HR, Bakker J, Lesaffre EM, le Noble JL. Neutrophil gelatinase-associated lipocalin at ICU admission predicts for acute kidney injury in adult patients. Am J Respir Crit Care Med 2011;183:907-14
21. Bolignano D, Lacquaniti A, Coppolino G, et al. Neutrophil Gelatinase-Associated Lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 2009;4:337-44
22. Mitsnefes M, Kathman T, Mishra J. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in children with chronic kidney disease. Pediatr Nephrol 2007;22:101-8
23. Bolignano D, Coppolino G, Campo S, et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is associated with severity of renal disease in proteinuric patients. Nephrol Dial Transplant 2008;23:414-16
24. Aghel A, Shrestha K, Mullens W, et al. Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J Card Fail 2010;16:49-54
25. Alvelos M, Lourenco P, Dias C, et al. Prognostic value of neutrophil gelatinase-associated lipocalin in acute heart failure. Int J Cardiol 2011; [Epub ahead of print]
26. Maisel AS, Mueller C, Fitzgerald RL, et al. Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL evaluation along with B-type NaTriuretic peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail 2011;13:846-51
27. Goetz DH, Willie ST, Armen RS, et al. Ligand preference inferred from the structure of neutrophil gelatinase associated lipocalin. Biochemistry 2000;39:1935-41
28. Hannson GK, Hellstrand M, Rymo L, et al. Interferon (IFN) Gamma inhibits both proliferation and expression of differentiation-specific alpha-smooth muscle actin in arterial smooth muscle cells. J Exp Med 1989;170:1595-608
29. Yan L, Borregaard N, Kjeldsen L, Moses MA. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 activity by NGAL. J Biol Chem 2001;276:37258-65
30. Yndestad A, Landrø Ueland T, et al. Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur J Heart Fail 2009;30:1229-36
31. Kafkas T, Matthew J, Yang J, et al. Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann Intern Med 2008;148:810-19
32. Freda BJ, Tang WH, Van Lente F, et al. Cardiac troponins in renal insufficiency: review and clinical implications. J Am Coll Cardiol 2002;40(12):2065-71
33. Alvelos M, Pimental R, Pinho E, et al. Neutrophil gelatinase-associated lipocalin in the diagnosis of type 1 cardio-renal syndrome in the general ward. Clin J Am Soc Nephrol 2011;6(3):476-81
34. Hawkins R. New biomarkers of acute kidney injury and the cardio-renal syndrome. Korean J Lab Med 2011;31(2):72-80
35. Torregrosa I, Montoliu C, Urios A, et al. Early biomarkers of acute kidney failure after heart angiography or heart surgery in patients with acute coronary syndrome or acute heart failure. Nefrologia 2012;32(1):44-52
36. Nishida M, Kawakatsu H, Okumura Y, Hamaoka K. Serum and urinary neutrophil gelatinase-associated lipocalin levels in children with chronic renal diseases. Pediatr Int 2010;52:563-8
37. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, et al. Neutrophil gelatinase-associated lipocalin (NGAL) correlations with cystatin C, serum creatinine and eGFR in patients with normal serum creatinine undergoing coronary angiography. Nephrol Dial Transplant 2007;22:295-6
38. Damman K, van Veldhuisen D, Navis G, et al. Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. Eur J Heart Fail 2008;10(10):997-1000
39. Bolignano D, Coppolino G, Lacquaniti A, Buemi M. From kidney to cardiovascular diseases: NGAL as a biomarker beyond the confines of nephrology. Eur J Clin Invest 2010;40(3):273-6
40. Daniels LB, Barrett-Connor E, Clopton P, et al. Plasma neutrophil gelatinase-associated lipocalin is independently associated with cardiovascular disease and mortality in community-dwelling older adults: the Rancho Bernardo study. J Am Coll Cardiol 2012;59(12):1101-9
41. Smith C, Damas JK, Otterdal K, et al. Increased levels of neutrophil-activating peptide-2 in acute coronary syndromes: possible role of platelet-mediated vascular inflammation. J Am Coll Cardiol 2006;48:1591-9
42. Paulsson J, Dadfar E, Held C, et al. Activation of peripheral and in vivo transmigrated neutrophils in patients with stable coronary artery disease. Atherosclerosis 2007;192:328-34
43. Elneihoum AM, Falke P, Axelsson L, et al. Leukocyte activation detected by increased plasma levels of inflammatory mediators in patients with ischemic cerebrovascular diseases. Stroke 1996;27:1734-8
44. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, et al. NGAL (neutrophil gelatinaseassociatedlipocalin) and cystatin C: are they good predictors of contrast nephropathy after percutaneous coronary interventions in patients with stable angina and normal serum creatinine? Int J Cardiol 2008;127:290-1
45. Bachorzewska-Gajewska H, Poniatowski B, Dobrzycki S. NGAL (neutrophil gelatinase-associated lipocalin) and L-FABP after percutaneous coronary interventions due to unstable angina in patients with normal serum creatinine. Adv Med Sci 2009;54(2):221-4
46. Nymo SH, Ueland T, Askevold CT, et al. The association between neutrophil gelatinase-associated lipocalin and clinical outcome in chronic heart failure: results from CORONA. J Intern Med 2012;271(5):436-43
47. Shrestha K, Borowski AG, Troughton RW, et al. Renal Dysfunction is a stronger determinant of systemic neutrophil gelatinase-associated lipocalin levels than myocardial dysfunction in systolic heart failure. J Card Fail 2011;17(6):472-8
48. Chen HH, Burnett JC Jr. The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. Proc Assoc Am Physicians 1999;111(5):406-16
49. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7
50. Maisel A, Mueller C, Adams K Jr, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008;10(9):824-39
51. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart 2005;91(5):606-12
52. Clerico A, Fontana M, Zyw L, et al. Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: a systematic review. Clin Chem 2007;53(5):813-22
53. Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 2006;27(3):330-7
54. Bibbins-Domingo K, Gupta R, et al. N-terminal fragment of the prohormone brain-type natriuretic peptide (NTproBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA 2007;297(2):169-76
55. Moertl D, Berger R, Struck J, et al. Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death. J Am Coll Cardiol 2009;53(19):1783-90
56. Potocki M, Breidthardt T, Reichlin T, et al. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure. J Intern Med 2010;267(1):119-29
57. Maisel A, Mueller C, Nowak R, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010;55(19):2062-76
58. Von Haehling S, Jankowska EA, Morgenthaler NG, et al. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. J Am Coll Cardiol 2007;50(20):1973-80
59. Morgenthaler NG, Struck J, Alonso C, et al. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 2005;51(10):1823-9
60. Maisel A, Mueller C, Nowak RM, et al. Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2011;58(10):1057-67
61. Weinberg EO, Shimpo M, Hurwitz S, et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003;107:721-6
62. Bhardwaj A, Januzzi JL Jr. ST2: a novel biomarker for heart failure. Expert Rev Mol Diagn 2010;10(4):459-64
63. Januzzi JL Jr, Peacock W, Maisel AS, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 2007;50(7):607-13
64. Kehl DW, Iqbal N, Fard A, et al. Biomarkers in acute myocardial injury. Transl Res 2012;159(4):252-64
65. de Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep 2010;7(1):1-8
66. McCullough PA, Olobatoke A, Vanhecke TE. Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. Rev Cardiovasc Med 2011;12(4):200-10
67. Grandin EW, Jarolim P, Murphy SA, et al. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. Clin Chem 2012;58(1):267-73
68. de Boer RA, Lok DJ, Jaarsma T, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011;43(1):60-8
69. Morrow DA, Cannon CP, Jesse RL, et al. National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation 2007;115(13):e356-75
70. Thygesen K, Mair J, Giannitsis E, et al. the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J 2012;33(18):2252-7
71. Januzzi JL Jr, Bamberg F, Lee H, et al. High-sensitivity troponin T concentrations in acute chest pain patients evaluated with cardiac computed tomography. Circulation 2010;121(10):1227-34
72. Saenger AK, Jaffe AS. The use of biomarkers for the evaluation and treatment of patients with acute coronary syndromes. Med Clin North Am 2007;91:657-81
73. Lin JC, Apple FS, Murakami MM, et al. Rates of positive cardiac troponin I and creatine kinase MB mass among patients hospitalized for suspected acute coronary syndromes. Clin Chem 2004;50(2):333-8
74. Stec JJ, Silbershatz H, Tofler GH, et al. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. Circulation 2000;102(14):1634-8
75. Lowe GD. Fibrinogen assays for cardiovascular risk assessment. Clin Chem 2010;56(5):693-5
76. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987;258(9):1183-6
77. Gotto AM Jr. Role of C-reactive protein in coronary risk reduction: focus on primary prevention. Am J Cardiol 2007;99(5):718-25
78. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111(12):1805-12
79. Clearfield MB. C-reactive protein: a new risk assessment tool for cardiovascular disease. J Am Osteopath Assoc 2005;105(9):409-16
80. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007;116(16):1832-44
81. Benn M, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A. Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study. Arterioscler Thromb Vasc Biol 2007;27(3):661-70
82. Ramjee V, Sperling LS, Jacobson TA. Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math. J Am Coll Cardiol 2011;58(5):457-63
83. Cromwell WC, Barringer TA. Low-density lipoprotein and apolipoprotein B: clinical use in patients with coronary heart disease. Curr Cardiol Rep 2009;11(6):468-75
84. Duriez P, Dallongeville J, Fruchart JC. Lipoprotein (a) as a marker for coronary heart disease. Br J Clin Pract Suppl 1994;77):51-8
85. Nordestgaard BG, Chapman MJ, Ray K, et al. European Atherosclerosis Society Consensus Panel. Lipoprotein (a) as a cardiovascular risk factor: current status. Eur Heart J 2010;31(23):2844-53
86. Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein (a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA 1996;276(7):544-8
87. Luc G, Bard JM, Arveiler D, et al. PRIME Study Group. Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis 2002;163(2):377-84
88. Bolignano D, Coppolino G, Lacquaniti A, et al. Pathological and prognostic value of urinary neutrophil gelatinase-associated lipocalin in macroproteinuric patients with worsening renal function. Kidney Blood Press Res 2008;31:274-9
89. Bolignano D, Donato V, Coppolino G, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis 2008;52:595-605
90. Elneihoum AM, Falke P, Hedblad B, et al. Leukocyte activation in atherosclerosis: correlation with risk factors. Atherosclerosis 1997;131:79-84
91. Alvelos M, Lourenco P, Dias C, et al. Prognostic value of neutrophil gelatinase-associated lipocalin in acute heart failure. Int J Cardiol 2011; [Epub ahead of print]
92. Bu DX, Hemdahl AL, Gabrielsen A, et al. Induction of neutrophil gelatinase-associated lipocalin in vascular injury via activation of nuclear factor-kappaB. Am J Pathol 2006;169:2245-53
93. Devarajan P. Neutrophil gelatinase-associated liopcalin: a promising biomarker for human acture kidney injury. Biomark Med 2010;4:265-80